Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,217.00
Bid: 7,223.00
Ask: 7,225.00
Change: -58.00 (-0.80%)
Spread: 2.00 (0.03%)
Open: 7,100.00
High: 7,300.00
Low: 7,013.00
Yest. Close: 7,275.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca Drug Roxadustat Increases Haemoglobin Levels In Two Trials

Fri, 8th Nov 2019 08:14

(Alliance News) - Drug major AstraZeneca PLC on Friday said trials of roxadustat showed the drug significantly increased haemoglobin levels in anaemic chronic kidney disease patients.

The phase three Olympus and Rockies trials both showed "significantly higher" levels of haemoglobin, which transports oxygen in the blood, in patients with anaemia from chronic kidney disease. Improvement was seen both in patients dependent on dialysis and those who were not.

Anaemia, where a person does not have enough red blood cells or haemoglobin, is especially prevalent in chronic kidney disease patients as damaged kidneys makes less of the hormone erythropoietin, which is necessary for the production of red blood cells.

The Olympus trial compared roxadustat against a placebo, while the Rockies trial compared it to epoetin alfa. Roxadustat showed a statistically significant improvement in haemoglobin levels versus placebo and against epoetin alfa.

Mene Pangalos, executive vice president of BioPharmaceuticals Research & Development at Astra, said: "Anaemia is a common, serious condition among patients with chronic kidney disease. It occurs when the body has fewer healthy red blood cells than normal and low levels of haemoglobin, which may leave patients fatigued and short of breath.

"Results from Olympus and Rockies reinforce the potential role that roxadustat could play in increasing haemoglobin levels and managing anaemia, which is often underdiagnosed and undertreated."

Shares in Astra were up 0.1% at 7,292.00 pence each in London on Friday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News

UPDATE 1-UK Plc shares skyrocket on Johnson's sweeping win

* FTSE 100 up 1%, FTSE 250 jumps 4.2%* Utilities, banks and retailers top risers* Utility sector soars as Corbyn steps down as Labour leader* National Grid, United Utilities up 5%* RBS, Lloyds jump more than 10% (Updates stock prices)By Thyagaraju A...

13 Dec 19 08:49

Thursday broker round-up

(Sharecast News) - Synthomer: JP Morgan upgrades to neutral with a target price of 300p.

12 Dec 19 13:38

UK BROKER RATINGS SUMMARY: Bank Of America Upgrades HSBC To Buy

UK BROKER RATINGS SUMMARY: Bank Of America Upgrades HSBC To Buy

12 Dec 19 09:32

AstraZeneca Receives Marketing Authorization In China For Imfinzi

AstraZeneca Receives Marketing Authorization In China For Imfinzi

12 Dec 19 08:35

AstraZeneca gets Imfinzi approval in China

(Sharecast News) - AstraZeneca announced on Thursday that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for 'Imfinzi' - durvalumab - for the treatment of patients with unresectable, stage 3 non-small cell lung cancer (NSCLC), whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

12 Dec 19 07:32

Astra's Trastuzumab Deruxtecan Achieves Tumour Response Rate Of 60.9%

Astra's Trastuzumab Deruxtecan Achieves Tumour Response Rate Of 60.9%

11 Dec 19 13:41

AstraZeneca-Daiichi drug halts cancer for months in first readout

Dec 11 (Reuters) - An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.Patients on trastuzumab ...

11 Dec 19 13:00

Tuesday broker round-up

(Sharecast News) - ASOS: HSBC upgrades to buy with a target price of 3,615p.

10 Dec 19 08:29

DeepMatter shares surge as it announces AstraZeneca collaboration

(Sharecast News) - DeepMatter shares surged on Monday, after it announced a collaboration with AstraZeneca to use digital technologies to improve the productivity and reproducibility of compound synthesis.

9 Dec 19 14:07

UK WINNERS & LOSERS SUMMARY: Tullow Plunges On Output Guidance Reset

UK WINNERS & LOSERS SUMMARY: Tullow Plunges On Output Guidance Reset

9 Dec 19 10:50

UPDATE 2-UK shares weaken, Tullow loses half its market cap

* FTSE 100, FTSE 250 down 0.1%* Tesco outshines the main index* Some domestic stocks gain on election optimism* Tullow Oil plummets after co cancels dividend, CEO exits (Adds company news items, updates share moves)By Muvija M and Shashwat AwasthiDe...

9 Dec 19 09:23

DeepMatter Shares Surge On AstraZeneca DigitalGlassware Collaboration

DeepMatter Shares Surge On AstraZeneca DigitalGlassware Collaboration

9 Dec 19 09:15

Positive Results From AstraZeneca Trial Of Calquence Drug In Leukaemia

Positive Results From AstraZeneca Trial Of Calquence Drug In Leukaemia

9 Dec 19 06:51

AstraZeneca, Merck Get Marketing Authorization In China For Lynparza

AstraZeneca, Merck Get Marketing Authorization In China For Lynparza

5 Dec 19 08:31

AstraZeneca's Lynparza approved for use in China

(Sharecast News) - Biopharmaceutical company AstraZeneca announced on Thursday that Lynparza had been approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.

5 Dec 19 08:27

Login to your account

Don't have an account? Click here to register.